SCHEMBL4876686

SCHEMBL4876686

Nc1ccc(-c2nnc(-c3ccncc3)o2)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 10/20 0.79
RAB9A P51151 10/20 0.79
TP53 P04637 3/20 0.75
PKM P14618 1/20 0.75
MEN1 O00255 3/20 0.68
KMT2A Q03164 3/20 0.68
KDM4E B2RXH2 9/20 0.66
ALDH1A1 P00352 7/20 0.66
HSD17B10 Q99714 7/20 0.66
HPGD P15428 6/20 0.66
SMN1; SMN2 Q16637 5/20 0.66
MAPT P10636 3/20 0.66
GLA P06280 1/20 0.66
ALOX15 P16050 1/20 0.66
ATAD2 Q6PL18 2/20 0.64
CA1 P00915 1/20 0.61
CA2 P00918 1/20 0.61
NFKB1 P19838 1/20 0.59
NFKB2 Q00653 1/20 0.59
RELA Q04206 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL601473 0.89 NPC1 (1.00) NPC1RAB9ATP53PKMMEN1
SCHEMBL9612006 0.87 PKM (0.90) NPC1RAB9ATP53PKMMEN1
SCHEMBL11965041 0.87 PKM (0.90) NPC1RAB9ATP53PKMMEN1
SCHEMBL4883712 0.87 PKM (1.00) NPC1RAB9ATP53PKMMEN1
SCHEMBL2766462 0.83 PKM (0.74) NPC1RAB9ATP53PKMMEN1
SCHEMBL26673871 0.83 NPC1 (0.78) NPC1RAB9ATP53PKMMEN1
SCHEMBL8650657 0.81 RAB9A (1.00) NPC1RAB9ATP53MEN1KMT2A
SCHEMBL1016773 0.79 MAPT (0.67) NPC1RAB9ATP53MEN1KMT2A
SCHEMBL18745789 0.79 MAPT (0.67) NPC1RAB9ATP53MEN1KMT2A
SCHEMBL3173832 0.79 NPC1 (0.79) NPC1RAB9ATP53MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080015193-A1 Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof AGRIUS GROUP, LLC. 2008-01-17 US claimed
WO-2007149395-A2 2,5-SUBSTITUTED OXAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER AMPHORA DISCOVERY CORPORATION (US) 2007-12-27 WO claimed
US-20080015193-A1 Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof AGRIUS GROUP, LLC. 2008-01-17 US disclosed
WO-2007149395-A2 2,5-SUBSTITUTED OXAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER AMPHORA DISCOVERY CORPORATION (US) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015193-A1 Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof ATP5ME, ATP5MG, ATP5MK NPC1 2981/4885RAB9A 3960/4885TP53 2741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.